<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861912</url>
  </required_header>
  <id_info>
    <org_study_id>GDREC2013109H(R1)</org_study_id>
    <nct_id>NCT01861912</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma</brief_title>
  <acronym>ACTION</acronym>
  <official_title>Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether compared with arsenic trioxide TACE alone,
      arsenic trioxide TACE and intravenous administration could further prolong the overall
      survival.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.</time_frame>
    <description>Time to progression in our study is defined as the time from a patient's enrollment to the time for disease progression (according to Recist1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.</time_frame>
    <description>Overall survival in our study is defined as the time from a patient's enrollment to the time for death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.</time_frame>
    <description>Quality of life is assessed according to the FACT-Hep questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.</time_frame>
    <description>Safety of our treatment plan will be assessed according to the Common Terminology Criteria for Adverse Events（CTCAE） 3.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Extrahepatic Metastasis Rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.</time_frame>
    <description>Extrahepatic metastasis rate is defined as the proportion of the extrahepatic metastasis for patients who were absent of extrahepatic metastasis at enrollment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Recurrence Rate</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years.</time_frame>
    <description>Recurrence rate is defined as the proportion of the recurrence in the patients.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">258</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Arsenic trioxide TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arsenic trioxide TACE+IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arsenic trioxide TACE: arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities.
Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9% sodium chloride solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Arsenic trioxide TACE</intervention_name>
    <description>Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities</description>
    <arm_group_label>Arsenic trioxide TACE</arm_group_label>
    <arm_group_label>Arsenic trioxide TACE+IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic trioxide intravenous infusion</intervention_name>
    <description>Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.</description>
    <arm_group_label>Arsenic trioxide TACE+IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lipiodol</intervention_name>
    <description>Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.</description>
    <arm_group_label>Arsenic trioxide TACE</arm_group_label>
    <arm_group_label>Arsenic trioxide TACE+IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl solution</intervention_name>
    <description>250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.</description>
    <arm_group_label>Arsenic trioxide TACE+IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed informed consent;

          -  Histological or clinical diagnosis of hepatocellular carcinoma（HCC）;

          -  The target lesion should had at least one diameter line available for measurement,
             with the maximum diameter ≥5cm and ≤10cm；

          -  Barcelona Clinic Liver Cancer staging B or C;

          -  Child-Pugh liver function class: score≤7；

          -  Eastern Cooperative Oncology Group performance 0 or 1;

          -  At least 12 weeks life expectancy;

          -  Never received systemic treatment, such as oral molecularly targeted drugs and
             systemic chemotherapy;

          -  Be able to abide by the treatment and follow-up plan；

          -  Adequate results for laboratory tests, including:

               1. Neutrophil count≥1.5×109/L, platelet count≥60×109 /L; hemoglobin≥85g/L;

               2. Total bilirubin≤51.3 μmol/L, albumin≥28 g/L,and alanine aminotransferase and
                  aspartate aminotransferase≤5 times the upper limit of the normal range;

               3. Amylase and lipase≤1.5 times the upper limit of the normal range

               4. Serum creatinine≤20 g/L

               5. Prothrombin time international normalized ratio ≤1.7; or prothrombin
                  time≤4seconds above control;

               6. Left ventricular ejection fraction≥50% according to two-dimensional
                  echocardiography;

          -  Contraception: during the trail and 12 weeks after the withdrawal, female of
             childbearing age (WOCBP), WOCBP whose male partners receive study drug or male must
             use appropriate contraceptive to avoid pregnancy;

        Exclusion Criteria:

          -  Disease should be excluded:

               1. CT / MRI showed diffuse lesions;

               2. Extrahepatic metastasis (metastasis in lungs not included);

               3. Invasion in the main portal vein / vena cava or other major vascular;

               4. Previous shunt surgery;

               5. PreviousTACE or transarterial embolization for HCC, unless there is a untreated
                  lesion;

               6. Hepatic encephalopathy in the past or present;

               7. Current ascites requiring treatment;

          -  Medical history and concomitant diseases:

               1. Previous or current cancer other than HCC, unless it is cervical carcinoma in
                  situ, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1).
                  Cancer having received curative treatment 5 years ago will not be excluded;

               2. Disease history in the cardiovascular system as the following:

             (a)Uncontrolled hypertension；(b)Congestive heart failure in New York Heart Association
             grade 3 or 4; (c)Active coronary artery disease within 12 months, unstable angina or
             newly diagnosed angina/myocardial infarction;(d)Arrhythmia requiring drugs other than
             β-blockers and digoxin;(e)Valvular heart disease ≥ CTCAE grade 2； c) Corrected QT
             interval (Fridericia)&gt; 450 ms confirmed by 2 ECGs in a row d) Thrombotic or embolic
             events within 6 months, e) Gastrointestinal bleeding within 6 months; f) Unstable and
             / or active stomach ulcer within 6 months, unless gastroscopy showed it to be fully
             recovered; g) Variceal bleeding within 6 months; h) Unhealed wound or ulcer, fracture
             within 3 months; i) Major surgery, open biopsy, or severe trauma within 3 weeks; j)
             History of organ transplant or subjects in the transplant waiting list; k)
             Uncontrolled abnormal thyroid function; l) HIV infection; m) Active or untreated
             hepatitis B;

          -  laboratory tests unsuitable for the enrollment：

               1. Hyponatremia, serum sodium &lt;130 mmol / L；

               2. Hypokalemia, serum potassium &lt;3.5 mmol / L；

          -  Allergic reactions to arsenic trioxide and any other drugs used in this trail;

          -  Forbidden therapies and/or drugs:

               1. Condensation treatment (e.g., warfarin or heparin);

               2. Chronic antiplatelet therapy (Aspirin ≥ 300 mg / day; clopidogrel ≥ 75 mg / day);

               3. Radiotherapy within 4 weeks;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ligong Lu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2013</study_first_submitted>
  <study_first_submitted_qc>May 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2013</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong General Hospital</investigator_affiliation>
    <investigator_full_name>Ligong Lu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>Arsenic trioxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Chlorotrianisene</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

